Author + information
Galectin-3 (Gal-3), a novel protein implicated in the development of systemic inflammation and fibrosis, has been shown to be elevated in patients with heart failure and is a strong predictor of morbidity and mortality in this condition. To date, no study has evaluated Gal-3 in patients with pulmonary hypertension (PH), a known inflammatory state, associated with significant RV dysfunction, whether in the setting of pulmonary arterial hypertension (PAH) or diastolic heart failure-induced PH (DHF-PH).
We measured Gal-3 using an ELISA kit (BG Medicine, Waltham, MA) in 92 individual samples obtained from 38 patients with PAH (mean PA pressure ≥25 mmHg and PCWP <15 mmHg) and 39 patients with DHF-PH (left ventricular ejection fraction ≥50%, mean PA pressure ≥25 mmHg and gradient PA-diastolic PCWP ≤5 mmHg).
Mean (SD) Gal-3 (ng/mL) for the entire cohort was 29.3 (14.2), with a mean (SD) of 26.6 (11.9) and 32.1 (15.7) in the PAH and DHF-PH, respectively (p=0.09). There was no correlation between Gal-3 levels and invasively measured hemodynamic variables (all p>0.05).
Gal-3 levels are significantly elevated in PH, regardless of etiology. Levels are considerably elevated over the accepted upper limit of normal for the Gal-3 assay (17.7 ng/mL), with comparable levels associated with > 30% 1-year mortality in patients with heart failure. Further study will be needed to assess the prognostic role of Gal-3 in PH and possible role as a future therapeutic target in this condition.
Poster Sessions, Expo North
Monday, March 11, 2013, 9:45 a.m.-10:30 a.m.
Session Title: Pulmonary Hypertension: Pre-Clinical, Clinical, Biomarkers
Abstract Category: 27. Pulmonary Hypertension
Presentation Number: 1294-147
- 2013 American College of Cardiology Foundation